{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:39:06Z","timestamp":1790861946715,"version":"4.1.0"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1097\/hco.0b013e32835018cd","type":"journal-article","created":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T06:35:14Z","timestamp":1327386914000},"page":"70-81","source":"Crossref","is-referenced-by-count":23,"title":["Advances in pediatric pulmonary arterial hypertension"],"prefix":"10.1097","volume":"27","author":[{"given":"Dunbar","family":"Ivy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-3-20210204","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4103\/2045-8932.83456","article-title":"A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011.","volume":"1","author":"Cerro","year":"2011","journal-title":"Pulm Circ"},{"key":"R4-3-20210204","first-page":"510","article-title":"The Swiss registry for pulmonary arterial hypertension: the paediatric experience.","volume":"137","author":"Fasnacht","year":"2007","journal-title":"Swiss Med Wkly"},{"key":"R5-3-20210204","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/hrt.2008.150086","article-title":"Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006.","volume":"95","author":"Haworth","year":"2009","journal-title":"Heart"},{"key":"R6-3-20210204","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.acvd.2009.12.001","article-title":"Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France.","volume":"103","author":"Fraisse","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"R7-3-20210204","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/CIRCULATIONAHA.110.969584","article-title":"Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005.","volume":"124","author":"Van Loon","year":"2011","journal-title":"Circulation"},{"key":"R9-3-20210204","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCULATIONAHA.111.026591","article-title":"Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term PAH disease management.","volume":"125","author":"Barst","year":"2012","journal-title":"Circulation"},{"key":"R10-3-20210204","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1136\/hrt.2009.182378","article-title":"Childhood idiopathic pulmonary arterial hypertension: a national cohort study.","volume":"96","author":"Moledina","year":"2010","journal-title":"Heart"},{"key":"R13-3-20210204","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1183\/09031936.00056110","article-title":"Pulmonary arterial hypertension: a comparison between children and adults.","volume":"37","author":"Barst","year":"2011","journal-title":"Eur Respir J"},{"key":"R14-3-20210204","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jpeds.2010.06.010","article-title":"Medical therapy for pediatric pulmonary arterial hypertension.","volume":"157","author":"Tissot","year":"2010","journal-title":"J Pediatr"},{"key":"R15-3-20210204","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/MOP.0b013e3283464a52","article-title":"Recent progress in understanding pediatric pulmonary hypertension.","volume":"23","author":"Abman","year":"2011","journal-title":"Curr Opin Pediatr"},{"key":"R16-3-20210204","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"R17-3-20210204","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4103\/2045-8932.83445","article-title":"Functional classification of pulmonary hypertension in children: report from the PVRI pediatric taskforce, Panama 2011.","volume":"1","author":"Lammers","year":"2011","journal-title":"Pulm Circ"},{"key":"R18-3-20210204","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1378\/chest.89.4.497","article-title":"Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension.","volume":"89","author":"Barst","year":"1986","journal-title":"Chest"},{"key":"R19-3-20210204","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/01.CIR.0000138104.83366.E9","article-title":"Outcomes in children with idiopathic pulmonary arterial hypertension.","volume":"110","author":"Yung","year":"2004","journal-title":"Circulation"},{"key":"R20-3-20210204","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0735-1097(98)00668-8","article-title":"Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing.","volume":"33","author":"Atz","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"R22-3-20210204","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/01.CIR.103.4.544","article-title":"Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms.","volume":"103","author":"Rimensberger","year":"2001","journal-title":"Circulation"},{"key":"R23-3-20210204","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00246-010-9645-5","article-title":"Vasodilator testing with nitric oxide andor oxygen in pediatric pulmonary hypertension.","volume":"31","author":"Barst","year":"2010","journal-title":"Pediatr Cardiol"},{"key":"R25-3-20210204","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1213\/01.ane.0000255732.16057.1c","article-title":"Perioperative complications in children with pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization.","volume":"104","author":"Carmosino","year":"2007","journal-title":"Anesth Analg"},{"key":"R26-3-20210204","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1460-9592.2008.02419.x","article-title":"Anesthetic management of children with pulmonary arterial hypertension.","volume":"18","author":"Friesen","year":"2008","journal-title":"Paediatr Anaesth"},{"key":"R27-3-20210204","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/ccd.22693","article-title":"Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry.","volume":"76","author":"Hill","year":"2010","journal-title":"Catheter Cardiovasc Interv"},{"key":"R28-3-20210204","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/01.CIR.99.9.1197","article-title":"Vasodilator therapy for primary pulmonary hypertension in children.","volume":"99","author":"Barst","year":"1999","journal-title":"Circulation"},{"key":"R29-3-20210204","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"R30-3-20210204","first-page":"23","article-title":"How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension Int J Clin Pract S","volume":"64","author":"Barst","year":"2010","journal-title":"uppl"},{"key":"R31-3-20210204","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1742-1241.2008.01811.x","article-title":"Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension.","volume":"160","author":"Doran","year":"2008","journal-title":"Int J Clin Pract Suppl"},{"key":"R32-3-20210204","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1086\/605320","article-title":"Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension.","volume":"30","author":"Ivy","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R33-3-20210204","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.amjcard.2003.12.031","article-title":"Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.","volume":"93","author":"Ivy","year":"2004","journal-title":"Am J Cardiol"},{"key":"R34-3-20210204","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.amjcard.2009.12.075","article-title":"Effectiveness of transition from intravenous epoprostenol to oralinhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.","volume":"105","author":"Melnick","year":"2010","journal-title":"Am J Cardiol"},{"key":"R35-3-20210204","first-page":"325","article-title":"Review of inhaled iloprost for the control of pulmonary artery hypertension in children.","volume":"5","author":"Tissot","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"R36-3-20210204","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2007.09.031","article-title":"Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension.","volume":"51","author":"Ivy","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R37-3-20210204","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijcard.2007.08.084","article-title":"Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease.","volume":"129","author":"Limsuwan","year":"2008","journal-title":"Int J Cardiol"},{"key":"R38-3-20210204","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R39-3-20210204","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jpeds.2010.09.025","article-title":"Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension.","volume":"158","author":"Levy","year":"2011","journal-title":"J Pediatr"},{"key":"R40-3-20210204","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.amjcard.2006.09.119","article-title":"Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.","volume":"99","author":"Ivy","year":"2007","journal-title":"Am J Cardiol"},{"key":"R41-3-20210204","first-page":"A6143","article-title":"Inhaled treprostinil in pediatric pulmonary arterial hypertension.","volume":"183","author":"Rosenzweig","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"R42-3-20210204","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension.","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"R43-3-20210204","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0009-9236(03)00005-5","article-title":"Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.","volume":"73","author":"Barst","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R44-3-20210204","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2174\/157016109787455653","article-title":"Bosentan in pediatric patients with pulmonary arterial hypertension.","volume":"7","author":"Beghetti","year":"2009","journal-title":"Curr Vasc Pharmacol"},{"key":"R45-3-20210204","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1203\/PDR.0b013e318179954c","article-title":"Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program.","volume":"64","author":"Beghetti","year":"2008","journal-title":"Pediatr Res"},{"key":"R46-3-20210204","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/hrt.2005.072314","article-title":"Response to bosentan in children with pulmonary hypertension.","volume":"92","author":"Maiya","year":"2006","journal-title":"Heart"},{"key":"R47-3-20210204","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2005.01.066","article-title":"Effects of long-term bosentan in children with pulmonary arterial hypertension.","volume":"46","author":"Rosenzweig","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R48-3-20210204","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1183\/09031936.00053510","article-title":"Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children.","volume":"38","author":"Hislop","year":"2011","journal-title":"Eur Respir J"},{"key":"R49-3-20210204","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.amjcard.2010.06.064","article-title":"Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings.","volume":"106","author":"Ivy","year":"2010","journal-title":"Am J Cardiol"},{"key":"R50-3-20210204","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1365-2125.2009.03532.x","article-title":"Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study.","volume":"68","author":"Beghetti","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R51-3-20210204","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.","volume":"114","author":"Galie","year":"2006","journal-title":"Circulation"},{"key":"R52-3-20210204","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/CIRCULATIONAHA.109.883876","article-title":"Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension.","volume":"121","author":"Dimopoulos","year":"2010","journal-title":"Circulation"},{"key":"R53-3-20210204","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension.","volume":"46","author":"Galie","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R54-3-20210204","first-page":"A3330","article-title":"Pharmacokinetics and safety of ambrisentan in pediatric patients with pulmonary arterial hypertension.","volume":"181","author":"Ivy","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R55-3-20210204","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension.","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"R56-3-20210204","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijcard.2004.09.002","article-title":"Safety and efficacy of sildenafil therapy in children with pulmonary hypertension.","volume":"100","author":"Karatza","year":"2005","journal-title":"Int J Cardiol"},{"key":"R57-3-20210204","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jpeds.2008.09.021","article-title":"Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease.","volume":"154","author":"Mourani","year":"2009","journal-title":"J Pediatr"},{"key":"R58-3-20210204","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S1047951110001745","article-title":"Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease.","volume":"21","author":"Humpl","year":"2011","journal-title":"Cardiol Young"},{"key":"R59-3-20210204","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1164\/rccm.200605-694OC","article-title":"Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children.","volume":"174","author":"Namachivayam","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R60-3-20210204","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1067\/mtc.2002.125265","article-title":"Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crisis.","volume":"124","author":"Atz Am","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R61-3-20210204","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.110.016667","article-title":"A randomized, double-blind placebo-controlled, dose-ranging study of oral sildenafil citrate in the treatment of children with pulmonary arterial hypertension.","volume":"125","author":"Barst","year":"2012","journal-title":"Circulation"},{"key":"R63-3-20210204","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1007\/s00134-003-2016-4","article-title":"Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery.","volume":"29","author":"Stocker","year":"2003","journal-title":"Intensive Care Med"},{"key":"R64-3-20210204","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jpeds.2009.06.012","article-title":"Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension.","volume":"155","author":"Steinhorn","year":"2009","journal-title":"J Pediatr"},{"key":"R65-3-20210204","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00134-010-2065-4","article-title":"Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease.","volume":"37","author":"Fraisse","year":"2011","journal-title":"Intensive Care Med"},{"key":"R66-3-20210204","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension.","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"R67-3-20210204","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1517\/14656560903413542","article-title":"Tadalafil for the treatment of pulmonary arterial hypertension.","volume":"11","author":"Rosenzweig","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"R69-3-20210204","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","article-title":"Imatinib for the treatment of pulmonary arterial hypertension.","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N Engl J Med"},{"key":"R70-3-20210204","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","article-title":"Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.","volume":"182","author":"Ghofrani","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R71-3-20210204","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.RES.0000157672.70560.7b","article-title":"Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease.","volume":"96","author":"Zhao","year":"2005","journal-title":"Circ Res"},{"key":"R72-3-20210204","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1161\/01.CIR.0000121684.52920.0E","article-title":"Cell therapy for pulmonary hypertension: what is the true potential of endothelial progenitor cells C","volume":"109","author":"Stewart","year":"2004","journal-title":"irculation"},{"key":"R73-3-20210204","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00072311","article-title":"Circulating fibrocytes are increased in children and young adults with pulmonary hypertension.","volume":"39","author":"Yeager","year":"2012","journal-title":"Eur Respir J"},{"key":"R74-3-20210204","first-page":"971","article-title":"Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.","volume":"10","author":"Belik","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"R75-3-20210204","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.","volume":"36","author":"Ghofrani","year":"2010","journal-title":"Eur Respir J"},{"key":"R76-3-20210204","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1183\/09031936.00039808","article-title":"First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.","volume":"33","author":"Grimminger","year":"2009","journal-title":"Eur Respir J"},{"key":"R77-3-20210204","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/13543784.2011.565048","article-title":"Riociguat for the treatment of pulmonary hypertension.","volume":"20","author":"Schermuly","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"R78-3-20210204","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/jpet.110.169748","article-title":"Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.","volume":"335","author":"Morrison","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R79-3-20210204","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00228-011-1043-2","article-title":"Macitentan: entry-into-humans study with a new endothelin receptor antagonist.","volume":"67","author":"Sidharta","year":"2011","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Current Opinion in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/HCO.0b013e32835018cd","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:30:46Z","timestamp":1786048246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001573-201203000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/hco.0b013e32835018cd","relation":{},"ISSN":["0268-4705"],"issn-type":[{"value":"0268-4705","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}